Immune Support Peptide Stack

The three peptides target different arms of the immune system and can be administered in parallel:

**Thymosin Alpha-1**: 1.6 mg subcutaneous injection, 2× per week. This is the approved dosing schedule (Zadaxin) for immune modulation. Cycles of 8–12 weeks with 4-week breaks. This is the backbone of the stack — the peptide with the deepest clinical evidence.

**LL-37**: 100 mcg subcutaneous injection, 3× per week. Dosing extrapolated from preclinical models — no established human therapeutic protocol. Used for periods of increased infectious risk or active immune challenge. Duration: 2–4 weeks as needed.

**KPV**: 200–500 mcg subcutaneous or oral, daily. The anti-inflammatory component — reduces NF-κB-driven inflammation that can impair immune function. Oral KPV targets intestinal mucosal immunity specifically. Duration: 4–8 weeks.

**Timing**: Thymosin Alpha-1 provides the sustained adaptive immune foundation. LL-37 adds acute antimicrobial support during high-risk periods. KPV modulates inflammatory tone that can suppress effective immune responses.